Bone Care International Amends Registration Statement To Sell 1,000,000 Shares of Common Stock.MADISON, Wis.--(BUSINESS WIRE)--July 14, 1998--Bone Care International Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :BCII BCII Battle Command and Intelligence Integration ) today announced the amendment of a registration statement filed with the Securities and Exchange Commission ("SEC") relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc a proposed public offering of 1,000,000 shares of the company's common stock. The shares are being offered on an any or all basis in a directed public offering by the company. No underwriter or placement agent will be engaged by the company in connection with the sale of the shares. The company intends to offer and sell the shares in a privately negotiated transaction between the company and the purchasers of the shares. Certain directors of the company have indicated they intend to purchase 300,000 of the shares being offered. Bone Care International is an emerging pharmaceutical company which is developing vitamin D-hormone therapies with improved safety and efficacy profiles for treatment of (a) secondary hyperparathyroidism secondary hyperparathyroidism Endocrinology ↑ Parathyroid activity with overproduction of PTH due to parathyroid hyperplasia in response to an extraparathyroid defect that results in ↓ Ca2+ Etiology Rickets, vitamin D deficiency, chronic renal failure associated with end stage renal disease Renal disease Kidney disease. Mentioned in: Glycogen Storage Diseases hypertension High blood pressure Cardiovascular disease An abnormal ↑ systemic arterial pressure, corresponding to a systolic BP of > 160 mm Hg , pre-dialysis renal disease, and osteoporosis, and (b) certain hyperproliferative diseases, including psoriasis and cancers of the breast, prostate and colon. A copy of the preliminary prospectus Preliminary Prospectus A first draft registration statement filed by a firm prior to proceeding with an initial public offering of securities. The document, filed with the Securities & Exchange Commission, is intended to provide pertinent information to prospective shareholders related to this offering may be obtained by contacting the company at One Science Court, Madison, Wisconsin 53711. A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sales of these securities in any state in which such offer, solicitation, or sale would be unlawful prior to registration or qualification un 608/236-2525 KEYWORD: WISCONSIN me page. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion